Coya Therapeutics, Inc. (COYA) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 98.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: -40.79%
• EPS Growth: -16.57%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -0.98
• Shares Outstanding: 16,724,998
• 10 Day Avg. Volume: 77,139
• 30 Day Avg. Volume: 98,131
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 31.44
• Price to Cash Flow (P/CF): -11.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $15.00
• Price Target Upside: 204.26% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Coya Therapeutics, Inc. faces challenges with profitability and cash flow, weighing heavily on its financial performance. While the technical indicators show a neutral stance, the stock's valuation is impacted by negative earnings. Recent corporate developments provide a positive outlook with advancements in clinical trials and strategic financing. However, immediate financial challenges remain the primary concern.

Positive Factors

Clinical Development

The COYA301 trial showed clear signs of cognitive efficacy as well as the expected biomarker readouts.

Financial Performance

Coya Therapeutics receives a one-time, non-dilutive funding of $3.85 million from Dr. Reddy's, providing immediate financial certainty for its clinical trial.

Regulatory Engagement

Productive meetings with the FDA have helped inform the design of the forthcoming phase II study for COYA 302, showcasing strong regulatory engagement.

Negative Factors

Clinical Trials

Coya's P2b trial in ALS is about to start, and investor interest in pipeline programs is leveraged to that readout.

Patient Safety

Safety and biological activity benchmarks met with no serious adverse events or deaths reported.

Coya Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Coya Therapeutics, Inc. (COYA) is a biotechnology company focused on developing innovative therapies for neurodegenerative and autoimmune diseases. The company leverages its expertise in regulatory T-cell (Treg) technology to create treatments that address the underlying causes of these conditions. Coya's core products are designed to modulate the immune system to enhance the body's natural ability to combat disease, offering new hope for patients with limited treatment options.

How the Company Makes Money

Coya Therapeutics, Inc. generates revenue through the development and commercialization of its proprietary therapies. The company primarily earns money by advancing its drug candidates through clinical trials, seeking regulatory approval, and ultimately bringing successful treatments to market. Revenue streams may include product sales, licensing agreements, and strategic partnerships with other biotechnology and pharmaceutical companies. These partnerships often involve collaborative research and development efforts, as well as milestone and royalty payments based on the successful commercialization of joint projects. Additionally, Coya may receive funding from grants or government programs aimed at supporting innovative medical research.

Coya Therapeutics, Inc. Financial Statement Overview

Summary

Coya Therapeutics, Inc. shows strong revenue growth and a debt-free balance sheet with substantial cash reserves. However, it is hampered by significant profitability and cash flow challenges, with negative EBIT and net income. The cash flow is strained due to negative operating and free cash flows, which highlights the need for strategic improvements in cost management.

Income Statement

Coya Therapeutics, Inc. has shown a massive increase in revenue in 2024, but the profitability remains a significant concern with negative EBIT and net income. The company has a gross profit margin of 100% due to revenue matching gross profit, but high operating losses lead to negative EBIT and net profit margins. The revenue growth from 2023 to 2024 is impressive but overshadowed by substantial net losses, suggesting the company struggles with profitability in scaling.

Balance Sheet

The balance sheet shows a strong equity position with no debt, resulting in a zero debt-to-equity ratio, which is favorable. The equity ratio is high, and the company has ample cash reserves relative to liabilities. However, the high net losses impact return on equity negatively. Overall, the balance sheet reflects financial stability with a robust cash position but is challenged by poor profitability metrics.

Cash Flow

Coya Therapeutics, Inc. has negative operating and free cash flows, indicating cash outflows surpass inflows from operations. There is no free cash flow growth, and both operating and free cash flows to net income ratios are negative, highlighting cash management challenges. Despite significant financing cash inflows, the cash flow situation remains strained due to continuous operational losses.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
3.55B	6.00M	0.00	0.00	0.00
	Gross Profit
3.55B	5.97M	-27.36K	-16.13K	0.00
	EBIT
-17.25B	-7.90M	-9.81M	-4.87M	-694.77K
	EBITDA
-17.22M	-7.90M	-12.22M	-4.85M	10.44K
	Net Income Common Stockholders
-14.88M	-7.99M	-14.68M	-4.87M	-733.20K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
38.34B	32.63M	5.93M	4.34M	8.72M
	Total Assets
44.35B	41.26M	8.40M	4.79M	8.75M
	Total Debt
0.00	0.00	12.97M	0.00	0.00
	Net Debt
-38.34M	-32.63M	7.03M	-4.34M	-8.72M
	Total Liabilities
4.77B	5.63M	16.79M	1.15M	447.12K
	Stockholders Equity
39.58B	35.64M	-8.39M	3.64M	8.30M
Cash Flow		Free Cash Flow
-10.29B	-11.19M	-7.24M	-4.04M	-391.27K
	Operating Cash Flow
-10.29B	-11.19M	-7.24M	-3.90M	-391.27K
	Investing Cash Flow
-25.00M	-543.19K	-525.00K	-136.80K	0.00
	Financing Cash Flow
16.03B	38.43M	9.36M	-340.58K	9.11M

Coya Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.93
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COYA, the sentiment is Negative. The current price of 4.93 is below the 20-day moving average (MA) of 6.13, below the 50-day MA of 6.39, and below the 200-day MA of 6.44, indicating a bearish trend. The MACD of 0.03 indicates Positive momentum. The RSI at 48.48 is Neutral, neither overbought nor oversold. The STOCH value of 52.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for COYA.

Coya Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CORT	78 Outperform	$7.70B	54.93	23.55%	―	39.94%	32.10%
ACAD	76 Outperform	$2.50B	10.38	38.89%	―	31.85%	―
AVXL	62 Neutral	$741.76M	―	-37.72%	―	―	-3.08%
AXSM	51 Neutral	$4.96B	―	-231.63%	―	42.53%	-15.29%
Sector *	48 Neutral	$6.25B	1.14	-46.26%	2.69%	19.24%	1.75%
COYA	46 Neutral		―	-39.56%	―	-40.79%	-16.57%
ANVS	38 Underperform	$24.94M	―	-3159.09%	―	―	68.75%

Coya Therapeutics, Inc. Corporate Events

Coya Therapeutics Reports 2024 Financial Results and Updates

Coya Therapeutics, Inc. provided a corporate update and reported its financial results for the fiscal year 2024, highlighting significant advancements in its clinical trials and financial positioning. The company announced positive outcomes from various studies, including improvements in inflammatory markers in Alzheimer’s patients and progress in trials for Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Financially, Coya raised $10 million through a private placement and received strategic investments to support its pipeline development. Despite a net loss increase to $14.9 million in 2024, the company remains optimistic about its future milestones and the potential of its therapeutic approaches to create shareholder value.